Drug resistance

Resource
December 19, 2017

HIV drug resistance (HIVDR) poses a threat to future antiretroviral therapy success. Monitoring HIVDR patterns is of particular importance in populations such as sex workers (SWs), where documented HIV prevalence is between 34-89%, and in countries with limited therapeutic options.

Resource
November 21, 2017

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

Resource
October 26, 2017

Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS.

Resource
September 5, 2017

Hepatitis B virus (HBV)–HIV coinfections are becoming common with information on HBV genetic diversity and drug resistance still remaining elusive.

Resource
July 21, 2017

This second HIV drug resistance (HIVDR) report provides an update on recent population levels of HIVDR covering the period 2014–2016.

Resource
June 22, 2017

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries.

Resource
March 27, 2017

Tuberculosis disproportionately affects hard-to-reach populations, such as homeless people, migrants, refugees, prisoners, or drug users. These people often face challenges in accessing quality health care.

Resource
March 24, 2017

Although the number of deaths worldwide from tuberculosis—a disease caused by the bacterium Mycobacterium tuberculosis—fell by 22% between 2000 and 2015, it remains humanity’s biggest infectious killer and one of the top ten causes of all deaths.

Resource
March 6, 2017

The Stop TB Partnership today launched its World TB Day website which has the full spectrum of downloadable communications materials.

Resource
February 28, 2017

The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments.